Melo M E, El-Amine M, Tonnetti L, Fleischman L, Scott D W
Dept of Immunology, American Red Cross, Jerome Holland Laboratory, Rockville, MD 20855, USA.
Int Rev Immunol. 2001 Oct;20(5):627-45. doi: 10.3109/08830180109045582.
Tolerance induction would be an ideal way to treat autoimmune diseases, especially if achievable in primed individuals. Moreover, specific tolerance would preclude the need for immunosuppressive treatment with its side effects. In this review, we will revisit the historical concepts of tolerance, and introduce a novel approach to tolerance via gene therapy. Our model system is based on the tolerogenicity of IgG carriers and B-cell antigen presentation. Results with this model demonstrate that it is simple and effective even in primed recipients, and has proven efficacy in three autoimmune models. We discuss the mechanisms of tolerance with fusion IgG's and analyze how our model of gene therapy approached can be utilized to fit in the future treatment of autoimmune conditions.
诱导耐受性将是治疗自身免疫性疾病的理想方法,尤其是在已致敏个体中能够实现的情况下。此外,特异性耐受性将避免使用具有副作用的免疫抑制治疗。在本综述中,我们将重温耐受性的历史概念,并介绍一种通过基因疗法诱导耐受性的新方法。我们的模型系统基于IgG载体的耐受性和B细胞抗原呈递。该模型的结果表明,即使在已致敏的受体中,它也是简单有效的,并且已在三种自身免疫模型中证明了疗效。我们讨论了融合IgG诱导耐受性的机制,并分析了我们的基因治疗模型如何能够应用于未来自身免疫性疾病的治疗。